CBD

Reviewed by Maya Chen, Cannabis Science Writer | Updated June 1, 2026

What Is CBD?

Cannabidiol (CBD) is one of over 100 identified cannabinoids produced in the trichomes of cannabis plants. It was first isolated in 1940 by chemist Roger Adams at the University of Illinois, though its full chemical structure wasn’t confirmed until 1963. Today, CBD is found in both high-THC cannabis strains and hemp cultivars bred to contain less than 0.3% THC by dry weight.

In my research, I find that people often assume CBD and THC are opposites. They share the same molecular formula (C₂₁H₃₀O₂) but differ in atomic arrangement. That single structural difference changes everything. THC binds directly and powerfully to CB1 receptors in the brain, triggering psychoactive effects. CBD, by contrast, has very low binding affinity for CB1 receptors and appears to work through a broader set of pathways, including serotonin receptors (5-HT1A), TRPV1 channels, and GPR55 receptors.

CBD is typically present in raw cannabis as its acidic precursor, CBDa (cannabidiolic acid). Heat converts CBDa into active CBD through a process called Decarboxylation, which is why raw cannabis flower contains mostly CBDa rather than CBD itself.

Why CBD Matters: Effects and Research

CBD is the most clinically studied cannabinoid after THC, with research spanning anxiety, epilepsy, inflammation, and neuroprotection. The FDA-approved drug Epidiolex, a purified CBD formulation, is the clearest evidence that CBD has measurable, reproducible biological effects in humans.

Research published in a 2021 review of CBD’s therapeutic efficacy identified significant evidence for CBD’s anticonvulsant properties and noted promising signals across anxiety and pain research, though the authors emphasized that many studies remain limited by small sample sizes and inconsistent dosing protocols. I always flag that caveat when discussing CBD science with readers.

Some studies indicate CBD may modulate the body’s endocannabinoid system without directly activating it, which partially explains why it doesn’t produce intoxication. A 2024 review published through PMC exploring CBD’s biological mechanisms found that CBD’s multi-receptor activity distinguishes it sharply from single-target pharmaceutical compounds, making it a genuinely interesting molecule from a pharmacology standpoint.

One area I find particularly compelling is CBD’s relationship with THC inside the plant itself. CBD appears to modulate THC’s psychoactive intensity, which is a central part of the Entourage Effect. For a deeper look at how these compounds interact with terpenes inside your body, see our detailed guide.

Research also suggests CBD may have anxiolytic properties. A review in The Journal of Clinical Medicine examining CBD’s impact on psychiatric conditions found that some studies indicate CBD reduces anxiety in both animal models and human subjects, though researchers consistently call for larger randomized controlled trials before drawing firm conclusions.

CBD in Cannabis Strains and Cannabinoid Ratios

The CBD content of a cannabis strain is determined by its genetics. Two genes, CBDA synthase and THCA synthase, compete for the same precursor molecule (CBGa). Strains with dominant CBDA synthase expression produce high CBD and low THC; strains with dominant THCA synthase produce the opposite. Most recreational cultivars today express less than 1% CBD, while hemp-derived CBD cultivars often reach 10–20% CBD with THC below the legal threshold.

In the recreational and medical cannabis market, cannabinoid ratios matter enormously. A 1:1 THC:CBD product feels substantially different from a 20:1 THC:CBD strain. I analyzed several high-CBD cultivars in my graduate research and found that even small amounts of CBD (2–4%) in an otherwise THC-dominant flower can noticeably soften the anxiety edge some consumers experience with high-THC products. That’s the entourage effect in practical action.

Strains like Charlotte’s Web (a hemp cultivar) were specifically bred for high CBD expression, while some cannabis cultivars like Harlequin and ACDC carry CBD percentages between 10–15% alongside moderate THC. If you’re growing and want to understand how Trichomes develop and when CBD peaks relative to THC, timing your harvest correctly becomes especially important. See our harvest timing guide for specifics.

CBD vs. THC: The Core Differences

Understanding how CBD differs from THC is the single most common question I get from readers new to cannabis science. Both are phytocannabinoids. Both originate from CBGa (cannabigerolic acid) inside the plant. The differences in what they do to the human body, however, are significant and well-documented.

THC binds directly to CB1 receptors in the brain with high affinity, producing psychoactive effects including euphoria, altered time perception, and increased appetite. CBD does not bind meaningfully to CB1 receptors and does not produce those effects. Research suggests CBD may actually act as a negative allosteric modulator at CB1 receptors, meaning it changes the receptor’s shape in a way that reduces THC’s ability to bind. That’s why higher-CBD strains often feel less intensely psychoactive even when THC content is substantial.

Neither cannabinoid is considered addictive in the traditional pharmacological sense. The CDC notes CBD is not impairing. THC does carry dependence potential with heavy, long-term use, while research consistently shows CBD does not share that profile.

For more definitions like this one, visit our full cannabis glossary.